N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent

Abstract

The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.

1 - 25 . (canceled) 
     
     
         26 . A method of treating cancer which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 
     
     
         27 . A method for reducing abnormal proliferation in a cancerous cell or inducing differentiation of a cancerous cell which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 
     
     
         28 . A method of inducing apoptosis in a cancerous cell which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 
     
     
         29 . A method of providing an anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 
     
     
         30 . A method of providing an anti-angiogenic effect which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 
     
     
         31 . The method according to  claim 26  wherein the cancer is oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer lymphoma and leukaemia. 
     
     
         32 . The method according to  claim 26  wherein the cancer is prostate cancer. 
     
     
         33 . The method according to  claim 26  wherein the cancer is SCLC, NSCLC, colorectal cancer, ovarian cancer and/or breast cancer. 
     
     
         34 . The method according to  claim 26  wherein the cancer is bladder cancer, oesophageal cancer, gastric cancer, melanoma, cervical cancer and/or renal cancer. 
     
     
         35 . The method according to  claim 26  wherein the cancer is endometrial, liver, stomach, thyroid, rectal and/or brain cancer. 
     
     
         36 . The method according to  claim 26  wherein the cancer is SCLC. 
     
     
         37 . The method according to  claim 26  wherein the cancer is NSCLC. 
     
     
         38 . The method according to  claim 26  wherein the cancer is colorectal cancer. 
     
     
         39 . The method according to  claim 26  wherein the cancer is ovarian cancer. 
     
     
         40 . The method according to  claim 26  wherein the cancer is breast cancer. 
     
     
         41 . The method according to  claim 26  wherein the cancer is in a metastatic state. 
     
     
         42 . The method according to  claim 26  wherein the cancer is in a non-metastatic state. 
     
     
         43 . The method according to  claim 26  wherein the cancer is renal, thyroid, lung, breast or prostate cancer and is producing bone metastases. 
     
     
         44 . A method of inhibiting bone metastases and inhibiting invasion which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 
     
     
         45 . A method of inhibiting bone metastases which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 
     
     
         46 . A method of preventing bone metastases which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 
     
     
         47 . A method of treating bone metastases which comprises administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man.